LENT Prognostic Score Malignant Pleural Effusion

The LENT score predicts survival in malignant pleural effusion using LDH, ECOG performance status, neutrophil‑to‑lymphocyte ratio, and tumor type 1 [Level I evidence].

Plasma fluid LDH, U/L
< 15000≥ 1500+1
ECOG Score
0 (asymptomatic)01 (symptomatic but ambulatory)+12 (symptomatic, in bed < 50% of day)+23-4 (symptomatic, in bed > 50% of day or bedbound)+3
Serum neutrophil-to-lymphocyte ratio (from CBC)
< 90≥ 9+1
Tumor type
Mesothelioma or hematologic malignancy0Breast or gynecologic cancer or RCC+1Lung or any other cancer+2

Indicações de Uso

Used in adults with confirmed malignant pleural effusion to estimate short‑term survival and guide discussions on goals of care and intensity of pleural interventions. Identifies low-, moderate-, and high‑risk groups using pleural LDH, ECOG status, neutrophil‑to‑lymphocyte ratio, and tumor type, validated to outperform ECOG alone for survival prediction 1 [Level I evidence]. Enables tailoring of pleurodesis vs indwelling catheter strategies and early palliative planning.

Insights e Precauções

Stratifies MPE survival using LDH, ECOG, NLR, and tumor type, giving clearer 1–6‑month mortality prediction than ECOG alone (median survivals 319, 130, 44 days) 1 [Level II evidence]. Use cautiously: it underestimates survival in EGFR‑mutant lung adenocarcinoma 2 [Level II evidence] and misclassifies sarcomatoid mesothelioma as low‑risk despite poor outcomes 3 [Level II evidence]. Not validated to guide treatment decisions (BTS 2023) 4 [Level II evidence].